Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.
Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo
Title and authors | Publication | Year |
---|---|---|
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
JT Huckaby, E Landoni, TM Jacobs, B Savoldo, G Dotti, SK Lai |
Journal for ImmunoTherapy of Cancer | 2021 |
Improving CAR T-Cell Persistence
V Pietrobon, LA Todd, A Goswami, O Stefanson, Z Yang, F Marincola |
International journal of molecular sciences | 2021 |
Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
AH M., JC Halpin, M Mollaei, SW Bell, N Hirankarn, AD McLellan |
Cancers | 2021 |
Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
SS Qin, AD Melucci, AC Chacon, PA Prieto |
Cells | 2021 |
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
M Caforio, E de Billy, BD Angelis, S Iacovelli, C Quintarelli, V Paganelli, V Folgiero |
Cancers | 2021 |
Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy
V Hofschröer, K Najder, M Rugi, R Bouazzi, M Cozzolino, A Arcangeli, G Panyi, A Schwab |
Frontiers in pharmacology | 2021 |
A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy
H Ren, K Cao, M Wang |
Frontiers in immunology | 2021 |
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy
I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg |
Genes and Immunity | 2021 |
Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
A Pasetto, YC Lu |
Frontiers in immunology | 2021 |
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
S Chandrasekaran, CR Funk, T Kleber, CM Paulos, M Shanmugam, EK Waller |
Frontiers in immunology | 2021 |
PI3Kδ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8+ T cells at the expense of central memory
JL Cannons, AV Villarino, SM Kapnick, S Preite, HY Shih, J Gomez-Rodriguez, Z Kaul, H Shibata, JM Reilley, B Huang, R Handon, IT McBain, S Gossa, T Wu, HC Su, DB McGavern, JJ OShea, PJ McGuire, G Uzel, PL Schwartzberg |
Cell Reports | 2021 |
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
DM Richards, C Merz, C Gieffers, A Krendyukov |
Cancer management and research | 2021 |
Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens
G Flores-Mendoza, N Rodríguez-Rodríguez, RM Rubio, IK Madera-Salcedo, F Rosetti, JC Crispín |
Frontiers in immunology | 2021 |
Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells
C Marton, P Mercier-Letondal, R Loyon, O Adotévi, C Borg, J Galaine, Y Godet |
Cancer Gene Therapy | 2021 |
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy
MP Gustafson, CM Wheatley-Guy, AC Rosenthal, DA Gastineau, E Katsanis, BD Johnson, RJ Simpson |
Journal for ImmunoTherapy of Cancer | 2021 |
Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers
Z Yang, L Li, A Turkoz, P Chen, R Harari-Steinfeld, M Bobbin, O Stefanson, H Choi, V Pietrobon, B Alphson, A Goswami, V Balan, A Kearney, D Patel, J Yang, D Inel, V Vinod, A Cesano, B Wang, KH Roh, LS Qi, FM Marincola |
Journal of Translational Medicine | 2021 |
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
B Deng, J Pan, Z Liu, S Liu, Y Chen, X Qu, Y Zhang, Y Lin, Y Zhang, X Yu, Z Zhang, X Niu, R Luan, M Ma, X Li, T Liu, , H Niu, AH Chang, C Tong |
Molecular Therapy — Methods & Clinical Development | 2021 |
Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
S Smirnov, A Petukhov, K Levchuk, S Kulemzin, A Staliarova, K Lepik, O Shuvalov, A Zaritskey, A Daks, O Fedorova |
Frontiers in immunology | 2021 |
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
W Gong, L Wang, S Stock, M Ni, M Schubert, B Neuber, C Kleist, A Hückelhoven-Krauss, D Wu, C Müller-Tidow, A Schmitt, H Shiku, M Schmitt, L Sellner |
Cells | 2021 |
LFA-1 in T cell priming, differentiation, and effector functions
Gerard A, Cope AP, Kemper C, Alon R, Köchl R |
Trends in Immunology | 2021 |